Pegfilgrastim Biosimilars Market Size, Share Analysis & Industry Growth 2032 | Coherus BioSciences, Mylan N.V., Biocon

The Pegfilgrastim Biosimilars Market is estimated to be valued at USD 1.85 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.2% from 2025 to 2032. Market expansion is fueled by increasing demand for more affordable biosimilar options to the original biologic medications among patients facing healthcare expenses. Biosimilars provide notable cost reductions in relation to their reference biologics, which increases the acquisition of pegfilgrastim biosimilars by hospitals and cancer treatment facilities. The increasing number of cancer cases globally enhances the demand for supportive care treatments like pegfilgrastim. Additionally, the expiration of patents for key reference biologic drugs allows for the market introduction of several new biosimilars. This can increase the availability of treatment for additional patients.

Updated Version of Sample Report Included:
https://www.marketdigits.com/request/sample/4942

Major Players in Pegfilgrastim Biosimilars Markets are:
Coherus BioSciences, Mylan N.V., Biocon, Sandoz (a Novartis division), Pfizer Inc., Apotex Inc., Cinfa Biotech, Gedeon Richter, Stada Arzneimittel AG, Mundipharma, Aurobindo Pharma, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Intas Pharmaceuticals, Biocad, Genor Biopharma, Qilu Pharmaceutical, Henlius Biotech

Industry News:

In May 2023, Amneal Pharmaceuticals launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Neulasta in a pre-filled syringe. Developed with Kashiv Biosciences, FYLNETRA is used to treat neutropenia in chemotherapy patients. The product has received an approved J-Code (Q5130) from CMS.

In June 2020, Pfizer Inc. announced that the USFDA had approved NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim). NYVEPRIA is indicated to reduce the risk of febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy.

"Connect with our team of research specialists and unlock the optimal solution for driving your business growth"

Global Pegfilgrastim Biosimilars Market Segmentation:

By Product Insights:
Pegfilgrastim Biosimilars
Pegfilgrastim Reference Product
By Application Insights:
Oncology
Chronic Neutropenia
Stem Cell Transplantation
Others

By Route of Administration Insights:
Subcutaneous
Intravenous

By Distribution Channel Insights:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

Know more about this report:
https://www.marketdigits.com/pegfilgrastim-biosimilars-market-1728460163

The following areas and countries are covered in the worldwide Pegfilgrastim Biosimilars Market file:

North America (US, Canada, Mexico)
Europe (Germany, France, UK, Russia, Italy)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Saudi Arabia, UAE), Egypt, Nigeria, and South Korea)

North America dominates the global pegfilgrastim biosimilars market with an estimated market share of 41.9% in 2025. The U.S. market alone accounts for over 40.6% share due to huge demand for biosimilars from healthcare facilities as well as favorable reimbursement policies promoting their usage over reference biologics. Furthermore, presence of large regional pharmaceutical companies with established manufacturing and distribution networks aids product accessibility. While Canada also contributes significantly, future growth may be tempered by pricing pressures from government payers.

Detailed industry forecast-Brief Introduction to the research report:

Additional information on company participants
Customized reports and analyst assistance are available upon request.
Recent market developments and potential future growth opportunities
Personalized regional/country reports upon request
New data sources are being integrated.
Increased focus on data privacy and security
Increased collaboration and co-creation

Key Features of the Pegfilgrastim Biosimilars Market Report: -

Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

Examine the market opportunities for stakeholders by identifying higher growth sections.

To study and analyze the global Pegfilgrastim Biosimilars Market industry status and forecast including key regions.

An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

It helps you make strategic business decisions and investment plans.
Finally, Pegfilgrastim Biosimilars Market is a valuable source of guidance for individuals and companies.

Discover More: Visit Our Website for Additional Reports!

https://www.globenewswire.com/news-release/2024/02/09/2826658/0/en/Bioinformatics-Market-is-Set-to-Reach-USD-28-6-Billion-by-2030-with-CAGR-of-13-73-MarketDigits.html

https://www.globenewswire.com/news-release/2024/02/09/2826835/0/en/Beverage-Packaging-Market-projected-to-reach-USD-214-8-Billion-by-2030-growing-at-a-CAGR-of-4-9-during-the-forecast-period-of-2023-2030-pronounced-by-MarketDigits-in-its-recent-stu.html

https://www.globenewswire.com/news-release/2024/02/09/2826892/0/en/Intravascular-Warming-Systems-Market-Surges-to-USD-1-006-Million-by-2030-Reflecting-an-9-25-Growth-MarketDigits.html

https://www.globenewswire.com/news-release/2024/02/09/2826911/0/en/Minimally-Invasive-Glaucoma-Surgery-MIGS-Devices-Market-is-Set-to-Reach-USD-777-9-Million-by-2030-with-CAGR-of-5-37-MarketDigits.html

https://www.globenewswire.com/news-release/2024/02/12/2827392/0/en/Plant-Based-Food-Market-Surges-to-USD-85-Billion-by-2030-Reflecting-an-9-95-Growth-MarketDigits.html

About Us

Founded in 2015, MarketDigits Consulting & Advisory Pvt Ltd is a leading business research and consulting firm. Our mission is to empower clients by identifying emerging opportunities and driving revenue growth across industries. We specialize in providing comprehensive market insights, advanced technology solutions, and actionable strategies that support operational and strategic decision-making.

With a focus on the full value chain, our expert team delivers high-quality syndicate research reports, proprietary databases, and consulting services to help clients navigate today's competitive and dynamic business environment. At MarketDigits, we use advanced analysis to uncover profitable opportunities, enabling businesses to make smart decisions and achieve sustainable success.

Contact Us:

+1 510-730-3200 | +1 276-206-2055

sales@marketdigits.com

1248 CarMia Way Richmond

VA 23235, United States

This release was published on openPR.